ICPAD 2019 – Enduring Materials

Please note: no video is available for the ICPAD presentations


Day 1 - Thursday, 21 November 2019

 Session 1: Redesigning studies and endpoints with immuno oncology
Chairs: Howard Gurney & Nielka van Erp

Ruth Plummer, MDChanges and challenges in early phase trial endpoints
Ruth Plummer
Newcastle University, UK

 Calvo, Emiliano 2019 120x160New designs for early clinical trials of IO drugs
Emiliano Calvo
START Madrid, Centro Integral Oncológico Clara Campal, Hospital Madrid Norte Sanchinarro, Madrid, Spain
  Abstract-driven presentations 

Prediction of Capecitabine induced Severe Toxicity using Machine Learning Techniques
Maël Steunou, France

 Long term pemetrexed-based cancer treatment leads to nephrotoxicity
Nikki De Rouw, the Netherlands
 Session 2: Imaging, genetics and environment
Chairs: Nielka van Erp & Stijn Koolen
 Jorritsma-Smit, Annelies 2019 120x160The use of radiolabeled and fluorescent monoclonal antibodies for molecular imaging in oncology
Annelies Jorritsma-Smit
University Medical Center Groningen, The Netherlands
 Schalken, Jack 2019 120x160The long and winding road of the clinical introduction of a biomarker
Jack Schalken
Radboud University Medical Centre, The Netherlands
  Abstract-driven presentations 
 Epigenetic Regulation of OCTN1-mediated Cytarabine Transport in Acute Myeloid Leukemia
Jason Anderson, USA
 Comprehensive Pan-Cancer analysis of somatic mutations in drug transporters to reveal acquired and intrinsic drug resistance in 3149 metastatic cancer patients
Wesley Van De Geer, the Netherlands
 Session 3: PK/PD studies and new strategies
Chairs: Maria Jesus Garrido & Lena Friberg

Piet van der Graaf, PhDHow system pharmacology can facilitate clinical drug development in oncology
Piet van der Graaf
Certara, the Netherlands


Mats Karlsson, PhD, FCP, FISoPImpact of immortal time and selection bias on exposure-response modelling
Mats Karlsson
Uppsala University, Sweden


Clinical pharmacology strategy for development and labelling of new medicine in the era of targeted therapy and accelerated approvals in oncology
Berges, Alienor 2019 120x160

Alienor Berges
Astrazeneca Cambridge, UK 

Schalkwijk, Stein 2019 120x160

Stein Schalkwijk
Astrazeneca Cambridge, UK

  Abstract-driven presentations 
 Quantitative modeling of inter-lesion and inter-organ variability of tumor size
(No permission given to publish slides)
Sreenath Krishnan, Sweden
 Population pharmacodynamics modelling of circulating lymphocyte count over time in chronic lymphocytic leukemia patients under ibrutinib treatment
Fanny Gallais, France

Day 2 - Friday, 22 November 2019

 Session 4: Optimal study design & biomarker selection and validation
Chairs: Michelle Rudek & Etienne Chatelut

Optimal study design of oncology trials
Patricia LoRusso
Yale Cancer Center, USA

 Jamois, Candice 2019 120x160Challenges in the development of immunotherapy
Candice Jamois
Roche, Switzerland
  Abstract-driven presentations 
 Pharmacokinetics and safety of pazopanib in frail elderly patients
Félicien Le Louedec, France
 Population pharmacokinetic and pharmacogenetic analysis of mitotane in adrenocortical carcinoma patients: towards individualized dosing
(No permission given to publish slides)

Anyue Yin, the Netherlands
 Session 5: Drug-Drug / Drug-Food / Drug-environmental interactions
Chairs: Ron Mathijssen & Howard Gurney

Nielka van Erp, PharmD, PhDDrug - Food interaction an unrealized potential
Nielka van Erp
Radboud University Medical Centre, The Netherlands


Etienne Chatelut, PharmD, PhDChallenges in treating geriatric patients with cancer
(No permission given to publish slides)

Etienne Chatelut
Toulouse University Cancer Institute-Oncopole, France

  Abstract-driven presentations 
 Modulation of CYP3A activity to increase the oral bioavailability of ibrutinib
(No permission given to publish slides)

Eric Eisenmann, USA
 Effects of dietary restriction in cancer patients receiving irinotecan
Ruben Van Eerden, the Netherlands
 Session 6: Dose individualization approaches
Chairs: Michelle Rudek & Etienne Chatelut

Neeltje Steeghs, MD, PhDDose individualization potential for oral targeted oncolytics
Neeltje Steeghs
Netherland Cancer Institute, the Netherlands


Stijn Koolen, PharmD, PhDDose individualization potential for checkpoint inhibitors
Stijn Koolen
Erasmus Medical Centre, The Netherlands

  Abstract-driven presentation 
 Influence of probenecid on the pharmacokinetics and pharmacodynamics of sorafenib
Koen Hussaarts, the Netherlands
 Correlation between sunitinib exposure and toxicity in a real-life patient cohort
Kim Westerdijk, the Netherlands